Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 3, 1999, Pages 513-517

  Grigsby, Perry W ^a   Winter, Kathryn ^b   Wasserman, Todd H ^a   Marcial, Victor ^h   Rotman, Marvin ^c   Cooper, Jay ^d   Keys, Henry ^e   Asbell, Sucha O ^f   Phillips, Theodore L ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTOG Headquarters   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NONE

Author keywords

Cervix; Misonidazole; Radiation; RTOG; Sensitizer

Indexed keywords

MISONIDAZOLE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MISONIDAZOLE; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 0032995268     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00054-1     Document Type: Article

References (12)

1. Marcial V.A. Carcinoma of the cervix present status and future . Cancer. 39:1977;945-958.
2. Meoz R.T., Spanos W.J., Doss L., et al. Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study. Am J Clin Oncol (CCT). 6:1983;417-422.
3. Bauer M., Leibel S., Wasserman T., et al. Effect of misonidazole dose on survival in patients with stage IIIB-IVA squamous cell carcinoma of the uterine cervix an RTOG randomized trial . Int J Radiat Oncol Biol Phys. 12:1986;1101-1103.
4. Leibel S., Bauer M., Wasserman T., et al. Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix Preliminary report of a Radiation Therapy Oncology Group randomized trial . Int J Radiat Oncol Biol Phys. 13:1987;541-549.
5. Breslow N. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika. 57:1970;579-594.
6. Kalbfleish J.D., Prentice R.L. The statistical analysis of failure time data. 1980;Wiley and Sons, New York.
7. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Can Chemother Rep. 50:1966;163-170.
9. Anonymous. The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix. Int J Radiat Oncol Biol Phys 1984;57:491-499.
10. Overgaard J., Bentzen S., Kolstad P., et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 16:1989;1069-1072.
11. Dische S., Chassagne D., Hope-Stone H.F., et al. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix An interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix . Radiother Oncol. 26:1993;93-103.
12. Denekamp J., McNally N.J., Fowler J.F., et al. Misonidazole in fractionated radiotherapy Are many small fractions best? Br J Radiol. 53:1980;981-990.